Industry Information

Urofollitropin supplier: Drug Precautions

  Urofollicle-stimulating hormone must only be used by a physician experienced in the treatment of infertility.

  The urofollicle-stimulating hormone can cause mild to moderate ovarian enlargement, which may be accompanied by abdominal distension and/or abdominal pain, which usually relieves within 2 to 3 weeks.

  A urofollicle-stimulating hormone can cause severe pulmonary complications (such as acute respiratory distress syndrome, exacerbation of asthma, etc.) and ovarian hyperstimulation syndrome, with rare reports of death.

Urofollitropin supplier: Drug Precautions

  A urofollicle-stimulating hormone can lead to ovarian hyperstimulation syndrome, which progresses rapidly within 24 hours to several days in severe cases, manifested as a sharp increase in vascular permeability, resulting in rapid accumulation of fluid in the thoracic and peritoneal cavities, including the pericardium. Early symptoms include severe pelvic pain, weight gain, nausea, and vomiting. Ovarian hyperstimulation syndrome can occur at the end of treatment, and reach its peak in 7 to 10 days. Follow-up should be followed up for at least 2 weeks after treatment with urinary follicle-stimulating hormone, and it will automatically relieve menstrual cramps. Severe cases require drug withdrawal and hospitalization.

  Can cause multiple births, and patients should be informed before the treatment.

  Follitropin is a prescription drug and must be prescribed by your doctor for your medical condition.

  The above is the relevant content summarized by the editor of Kangyuan Company. If you want to know more, please continue to pay attention to us. We will regularly update you about Human chorionic gonadotropin, Human Menopausal Gonadotropin supplier, Urofollitropin price, Urokinase manufacturer, and Hormone API Manufacturer Related content, hope to help you.